Plumbagin is a constitutive metabolite of plants including Plumbago zeylanica L. , ' Plumbago i n d i c~,~ Plumbago europaea (Pl~mbaginaceae)~ and is also found to accumulate a s a secondary stress metabolite. Plumbagin is among several phytoalexins accumula.ted during the incompatible interaction beheen the parasitic Cuscuta reflexa (Convolvulaceae) and t h e host Ancistrocladus heyneanus (Ancistr~cladaceae).~ This leads to the degeneration of haustoria in the invading parasite and eventually its a b~r t i o n .~ Plumbagin was shown to display antibacterial and antifungal proper tie^.'.^.^ I t also causes mortality of Culex fatigans mosquito larvae,I inhibition of nematode larvae8 and exhibits cytotoxic: antiturnour and radiomodifying properties.1° Ethnomedical claims on I? zeylanica are reported from many parts of the world.11J2 The plant is used in many Asian countries to increase digestive powers, promote appetite and treat dyspepsia, piles, anasarca, skin diseases and fever.13 Numerous pharmacological investigations have been carried out on I? zeylanica

MicroRNA(miRNA)s have been identified as an emerging class for therapeutic interventions mainly due to their extracellularly stable presence in humans and animals and their potential for horizontal transmission and action. However, treating Type 2 diabetes mellitus using this technology has yet been in a nascent state. MiRNAs play a significant role in the pathogenesis of Type 2 diabetes mellitus establishing the potential for utilizing miRNA-based therapeutic interventions to treat the disease. Recently, the administration of miRNA mimics or antimiRs in-vivo has resulted in positive modulation of glucose and lipid metabolism. Further, several cell culture-based interventions have suggested beta cell regeneration potential in miRNAs. Nevertheless, few such miRNA-based therapeutic approaches have reached the clinical phase. Therefore, future research contributions would identify the possibility of miRNA therapeutics for tackling T2DM. This article briefly reported recent developments on miRNA-based therapeutics for treating Type 2 Diabetes mellitus, associated implications, gaps, and recommendations for future studies.